67
Participants
Start Date
November 30, 2013
Primary Completion Date
June 30, 2016
Study Completion Date
June 30, 2016
Trastuzumab
Trastuzumab (Herceptin) will be administered at a loading dose of 8 mg/kg (on day 1) followed by 6mg/kg i.v. infusion every 3 weeks (q3w), until disease progress or intolerable toxicity.
Docetaxel
Docetaxel 60mg/m2 (on day 1) every 3 weeks for 6 cycles.
Capecitabine
Capecitabine (Xeloda) 2000mg/m2d, d1-14, every 3 weeks until disease progress or intolerable toxicity.
Medical Oncology,Sun Yat-sen University Cancer Center, Guangzhou
Fudan University
OTHER
307 Hospital of PLA
OTHER
Shandong Tumor Hospital
OTHER
Tongji Hospital
OTHER
West China Hospital
OTHER
Shandong Provincial Hospital
OTHER_GOV
Second Affiliated Hospital of Suzhou University
OTHER
Tianjin Medical University General Hospital
OTHER
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Sixth Affiliated Hospital, Sun Yat-sen University
OTHER
Nanfang Hospital, Southern Medical University
OTHER
Sun Yat-sen University
OTHER